论文部分内容阅读
目的比较不同剂量沙美特罗替卡松辅助治疗支气管哮喘的临床疗效。方法选取2016年1月—2017年2月于南京市鼓楼区模范西路社区卫生服务中心收治的支气管哮喘患者86例,随机分为低剂量组与高剂量组,各43例。患者入院后均给予基础治疗,低剂量组患者给予吸入型50/250μg沙美特罗替卡松,高剂量组患者给予吸入型50/500μg沙美特罗替卡松,两组患者均持续治疗5周。比较两组患者治疗1、3、5周肺功能指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV1)与呼气峰流速(PEFR)]、哮喘症状评分(日间评分、夜间评分)。结果治疗1周,高剂量组患者FVC、FEV1和PEFR高于低剂量组,日间评分和夜间评分低于低剂量组(P<0.05),治疗3、5周,两组患者FVC、FEV1、PEFR及日间评分、夜间评分比较,差异无统计学意义(P>0.05)。结论对于支气管哮喘急性发作期患者,应首选高剂量沙美特罗替卡松;对于稳定期患者,应首选低剂量沙美特罗替卡松。
Objective To compare the clinical efficacy of different doses of salmeterol and ticlazuril in the treatment of bronchial asthma. Methods Totally 86 patients with bronchial asthma admitted from January 2016 to February 2017 in Model Welfare Community Health Service Center, Gulou District, Nanjing City were randomly divided into low dose group and high dose group, with 43 cases in each group. Patients were given basic therapy after admission. Patients in the low-dose group were given inhaled 50/50 μg salmeterol and those in the high-dose group were given inhaled 50/500 μg salmeterol. The patients in both groups were treated for 5 weeks . The lung function indexes (FVC, FEV1 and PEFR), asthma symptom score (daytime score, nighttime score). Results After 1 week of treatment, the FVC, FEV1 and PEFR in the high-dose group were higher than those in the low-dose group, the daytime scores and nighttime scores were lower than those in the low-dose group (P <0.05) PEFR and daytime scores, nighttime scores, the difference was not statistically significant (P> 0.05). Conclusions For patients with acute exacerbation of bronchial asthma, high dose salmeterol should be the first choice, and low dose salmeterol should be the first choice for stable patients.